Dividend Sweden (DIV) Q1 2026 earnings summary

Executive summary

• Net revenue for Q1 2026 was 2.8 MSEK, down from 5.5 MSEK year-over-year, reflecting lower market activity and no share distribution deals.

• Net loss after tax was -1.5 MSEK compared to a profit of 2.1 MSEK in Q1 2025, mainly due to a 1.4 MSEK loss from the bankruptcy of Solifokus Sverige AB.

• Result per share was -0.015 SEK, down from 0.022 SEK year-over-year.

• Portfolio company Evendo reported record demand and strong financial growth, while Medicortex is nearing public listing via a reverse acquisition.

Financial highlights

• Operating income for Q1 2026 was -1.1 MSEK, compared to 2.2 MSEK in Q1 2025.

• Equity at period end was 65.2 MSEK, down from 69.7 MSEK a year earlier.

• Cash and bank balances were 0.2 MSEK at quarter end, compared to 0.5 MSEK in Q1 2025.

• Value of the share portfolio was 68.5 MSEK at quarter end, down from 72.2 MSEK year-over-year.

Outlook and guidance

• Management expects continued challenging conditions for small-cap financing but notes increasing business activity and more companies preparing for listings.

• Plans to distribute Medicortex shares to shareholders remain, with additional dividends anticipated during the year.

• Anticipates a strong 2026 for Evendo, driven by rapid organic growth and AI integration.